Expression of cytochrome P450 isozyme transcripts and activities in human livers

References

• Achour, B., et al., 2014. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug metabolism and disposition, 42 (4), 500–510.
   PubMed Web of Science ®Google Scholar
• Anderson, G.D., 2008. Gender differences in pharmacological response. International review of neurobiology, 83, 1–10.
   PubMed Web of Science ®Google Scholar
• Bethke, L., et al., 2007. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC cancer, 7 (1), 123.
   PubMed Web of Science ®Google Scholar
• Boobis, A., et al., 2009. Drug interactions. Drug metabolism reviews, 41 (3), 486–527.
   PubMed Web of Science ®Google Scholar
• Chen, J., et al., 2019. A comprehensive review of cytochrome P450 2E1 for xenobiotic metabolism. Drug metabolism reviews, 51 (2), 178–195.
   PubMed Web of Science ®Google Scholar
• Croom, E.L., Wallace, A.D., and Hodgson, E., 2010. Human variation in CYP-specific chlorpyrifos metabolism. Toxicology, 276 (3), 184–191.
   PubMed Web of Science ®Google Scholar
• Finkelstein, D., et al., 2006. ADME transcriptome in Hispanic versus White donor livers: evidence of a globally enhanced NR1I3 (CAR, constitutive androstane receptor) gene signature in Hispanics. Xenobiotica, 36 (10–11), 989–1012.
   PubMed Web of Science ®Google Scholar
• Gao, N., et al., 2016. Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes. European journal of pharmaceutical sciences: official journal of the European federation for pharmaceutical sciences, 92, 86–97.
   PubMed Web of Science ®Google Scholar
• Gómez-Lechón, M.J., Castell, J.V., and Donato, M.T., 2007. Hepatocytes-the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chemico-biological interactions, 168 (1), 30–50.
   PubMed Web of Science ®Google Scholar
• Gonzalez, F.J., 2007. The 2006 Bernard B. Drug metabolism and disposition, 35 (1), 1–8.
   PubMed Web of Science ®Google Scholar
• Gorski, J.C., et al., 2003. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clinical pharmacology & therapeutics., 74 (3), 275–287.
   PubMed Web of Science ®Google Scholar
• Gröer, C., et al., 2014. Absolute protein quantification of clinically relevant cytochrome P450 enzymes and UDP-glucuronosyltransferases by mass spectrometry-based targeted proteomics. Journal of pharmaceutical and biomedical analysis, 100, 393–401.
   PubMed Web of Science ®Google Scholar
• Guengerich, F.P., 2008. Cytochrome p450 and chemical toxicology. Chemical research in toxicology, 21 (1), 70–83.
   PubMed Web of Science ®Google Scholar
• Hart, S.N., et al., 2009. Three patterns of cytochrome P450 gene expression during liver maturation in mice. Drug metabolism and disposition: the biological fate of chemicals, 37 (1), 116–121.
   PubMed Web of Science ®Google Scholar
• Hernandez, J.P., et al., 2009. Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR). Toxicology, 256 (1–2), 53–64.
   PubMed Web of Science ®Google Scholar
• Hines, R.N., 2007. Ontogeny of human hepatic cytochromes P450. Journal of biochemical and molecular toxicology, 21 (4), 169–175.
   PubMed Web of Science ®Google Scholar
• Hu, Z.Y. and Zhao, Y.S., 2010. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis. Drug metabolism and disposition, 38 (5), 817–823.
   PubMed Web of Science ®Google Scholar
• Johansson, I. and Ingelman-Sundberg, M., 2011. Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicological sciences: an official journal of the society of toxicology, 120 (1), 1–13.
   PubMed Web of Science ®Google Scholar
• Kadlubar, S., et al., 2009. Phenotypic CYP2A6 variation and the risk of pancreatic cancer. JOP: journal of the pancreas, 10 (3), 263–270.
   PubMedGoogle Scholar
• Lecluyse, E.L. and Alexandre, E., 2010. Isolation and culture of primary hepatocytes from resected human liver tissue. Methods in molecular biology, 640, 57–82.
   PubMedGoogle Scholar
• Loboz, K.K., et al., 2006. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clinical pharmacology and therapeutics, 80 (1), 75–84.
   PubMed Web of Science ®Google Scholar
• Man, M., et al., 2010. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. Journal of clinical pharmacology, 50 (8), 929–940.
   PubMed Web of Science ®Google Scholar
• Michaels, S. and Wang, M.Z., 2014. The revised human liver cytochrome P450 “Pie”: absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug metabolism and disposition: the biological fate of chemicals, 42 (8), 1241–1251.
   PubMed Web of Science ®Google Scholar
• Parkinson, A., et al., 2004. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicology and applied pharmacology, 199 (3), 193–209.
   PubMed Web of Science ®Google Scholar
• Poland, R.A., et al., 2002. Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans. Clinical pharmacology and therapeutics, 72 (3), 288–293.
   PubMed Web of Science ®Google Scholar
• Renaud, H.J., et al., 2011. Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. Toxicological sciences, 124 (2), 261–277.
   PubMed Web of Science ®Google Scholar
• Roddam, P.L., et al., 2000. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics, 10 (7), 605–615.
   PubMedGoogle Scholar
• Sadler, N.C., et al., 2016. Hepatic cytochrome P450 activity, abundance, and expression throughout human development. Drug metabolism and disposition: the biological fate of chemicals, 44 (7), 984–991.
   PubMed Web of Science ®Google Scholar
• Simon, T., et al., 2001. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. British journal of clinical pharmacology, 52 (5), 601–604.
   PubMed Web of Science ®Google Scholar
• Solus, J.F., et al., 2004. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics, 5 (7), 895–931.
   PubMed Web of Science ®Google Scholar
• Stevens, J.C., et al., 2008. Developmental changes in human liver CYP2D6 expression. Drug metabolism and disposition: the biological fate of chemicals, 36 (8), 1587–1593.
   PubMed Web of Science ®Google Scholar
• Wang, X., et al., 2020. Comparative proteomics analysis of human liver microsomes and S9 fractions. Drug metabolism and disposition, 48 (1), 31–40.
   PubMed Web of Science ®Google Scholar
• Wang, H. and Tompkins, L.M., 2008. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Current drug metabolism, 9 (7), 598–610.
   PubMed Web of Science ®Google Scholar
• Waxman, D.J. and Holloway, M.G., 2009. Sex differences in the expression of hepatic drug metabolizing enzymes. Molecular pharmacology, 76 (2), 215–228.
   PubMed Web of Science ®Google Scholar
• Yang, J., et al., 2006. Genetic polymorphisms in the cytochrome P450 1A1 and 2E1 genes, smoking, drinking and prostate cancer susceptibility: a case-control study in a Han nationality population in Southern China. International journal of urology: official journal of the Japanese urological association, 13 (6), 773–780.
   PubMed Web of Science ®Google Scholar
• Zhang, H.F., et al., 2016. Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human normal liver microsomes. The journal of pharmacology and experimental therapeutics, 358 (1), 83–93.
   PubMed Web of Science ®Google Scholar